Table 1—

Baseline demographic characteristics and subject enrollment and attrition

IAspBRLispro
Number of subjects treated595928
Age (years)42.3 ±12.043.1 ±9.439.9 ±11.1
Sex (male/female)23 (39)/36 (61)19 (32)/40 (68)9 (32)/19 (68)
BMI (kg/m2)26.7 ±3.825.9 ±3.826.3 ±3.2
Race (Caucasians)58 (98)58 (98)26 (93)
HbA1c (%)7.3 ±0.77.5 ±0.87.3 ±0.7
Insulin dose (units/kg)
 Total0.7 ±0.760.6 ±0.180.5 ±0.19
 Bolus0.4 ±0.570.3 ±0.130.2 ±0.14
 Basal0.3 ±0.230.3 ±0.130.3 ±0.11
Completed study55 (93)50 (85)27 (96)
Total withdrawn*4 (7)9 (15)1 (4)
Adverse event1 (2)00
  • *

    * Data are means ±SD or n (%). *Withdrawal reasons include withdrawal of consent, lack of compliance, lost to follow-up, ineffective therapy, and adverse event;

  • subject had herpes zoster.